» Articles » PMID: 30109466

Disease Progression in Parkinson Subtypes: the PPMI Dataset

Overview
Journal Neurol Sci
Specialty Neurology
Date 2018 Aug 16
PMID 30109466
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Discrete patterns of progression have been suggested for patients with Parkinson disease and presenting tremor dominant (TD) or postural instability gait disorders (PIGD). However, longitudinal prospective assessments need to take into consideration the variability in clinical manifestations and the evidence that only 40% of initially classified PIGD remain in this subtype at subsequent visits.

Methods: We analyzed clinical progression of PIGD compared to TD using longitudinal clinical data from the PPMI. Given the reported instability of such clinical classification, we only included patients who were reported as PIGD/TD at each visit during the 4-year observation. We used linear mixed-effects models to test differences in progression in these subgroups in 51 dependent variables.

Results: There were 254 patients with yearly assessment. The number of PIGD was 36/254 vs 144/254 TD. PIGD had more severe motor disease at baseline but progressed faster than TD only in three non-motor items of the MDS-UPDRS: cognitive impairment, hallucinations, and psychosis plus features of DDS. Our analysis also showed in PIGD faster increase in the average time with dyskinesia.

Conclusions: PIGD are characterized by more severe disease manifestations at diagnosis and greater cognitive progression, more frequent hallucinations, psychosis as well as features of DDS than TD patients. We interpret these findings as expression of greater cortical and subcortical involvement in PIGD already at onset. Since PIGD/TD classification is very unstable at onset, our analysis based on stricter definition criteria provides important insight for clinical trial stratification and definition of related outcome measures.

Citing Articles

Machine learning analysis of population-wide plasma proteins identifies hormonal biomarkers of Parkinson's Disease.

Chaudhry F, Kim T, Elemento O, Betel D medRxiv. 2025; .

PMID: 39763525 PMC: 11703317. DOI: 10.1101/2024.12.21.24313256.


Medication recommendation for Parkinson's disease based on dynamics of symptom progression.

Oh M, Kim H, Lee H Sci Rep. 2024; 14(1):25051.

PMID: 39443590 PMC: 11499640. DOI: 10.1038/s41598-024-76941-6.


Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.

Ajalin R, Al-Abdulrasul H, Tuisku J, Hirvonen J, Lahdenpohja S, Rinne J Mov Disord. 2024; 40(1):163-167.

PMID: 39435606 PMC: 11752992. DOI: 10.1002/mds.30042.


Comparing smell identification ability among different motor subtypes of Parkinson's disease using the Vietnamese Smell Identification Test and the Brief Smell Identification Test.

Huyen Thi Dang T, Truong D, Vinh Nguyen K, Le Ngoc Ha U, Chung Ngoc Vo K, Nguyen T Clin Park Relat Disord. 2024; 11:100270.

PMID: 39318472 PMC: 11420436. DOI: 10.1016/j.prdoa.2024.100270.


Unraveling the threads of stability: A review of the neurophysiology of postural control in Parkinson's disease.

Bath J, Wang D Neurotherapeutics. 2024; 21(3):e00354.

PMID: 38579454 PMC: 11000188. DOI: 10.1016/j.neurot.2024.e00354.


References
1.
Kelly V, Johnson C, McGough E, Shumway-Cook A, Horak F, Chung K . Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(7):692-7. PMC: 4524498. DOI: 10.1016/j.parkreldis.2015.04.002. View

2.
Abbruzzese G, Barone P, Ceravolo R, Fabbrini G, Lessi P, Ori A . Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. Neurol Sci. 2015; 36(6):935-43. DOI: 10.1007/s10072-014-2060-6. View

3.
Stebbins G, Goetz C, Burn D, Jankovic J, Khoo T, Tilley B . How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013; 28(5):668-70. DOI: 10.1002/mds.25383. View

4.
Laird N, Ware J . Random-effects models for longitudinal data. Biometrics. 1982; 38(4):963-74. View

5.
van Rooden S, Colas F, Martinez-Martin P, Visser M, Verbaan D, Marinus J . Clinical subtypes of Parkinson's disease. Mov Disord. 2011; 26(1):51-8. DOI: 10.1002/mds.23346. View